Ionis Pharmaceuticals (IONS) said Monday that the company and partner AstraZeneca's (AZN) Wainzua received approval in the European Union to treat hereditary transthyretin-mediated amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy, or ATTRv-PN.
Wainzua was approved for ATTRv-PN treatment in the US in December 2023 and has received approvals in other countries, including the UK and Canada, the company said.
ATTRv-PN results in peripheral nerve damage with motor disability within five years of diagnosis. Without treatment, the disease is "generally fatal" within 10 years, Ionis said.
Shares of Ionis rose 1.4% in recent premarket activity, while AstraZeneca fell 1.7%.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。